Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: A phase I study in patients with advanced solid malignancies Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Neoplasms
  • Receptor, Epidermal Growth Factor

abstract

  • Dual EGFR inhibition with cetuximab and erlotinib is feasible; the observed toxicities were manageable and consistent with the safety profiles of the individual drugs. The recommended doses for phase II studies are 250 mg/m(2) i.v. weekly for cetuximab and 150 mg daily orally for erlotinib.

publication date

  • February 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5310714

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2008-0124

PubMed ID

  • 19182243

Additional Document Info

start page

  • 119

end page

  • 24

volume

  • 14

number

  • 2